Intra-amniotic injection of DIGOXIN — Competitive Intelligence Brief

Intra-amniotic injection of DIGOXIN (Intra-amniotic injection of DIGOXIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cardiac glycoside. Area: Cardiology.

phase 3 Cardiac glycoside Na+/K+-ATPase Cardiology Small molecule

Target snapshot

Intra-amniotic injection of DIGOXIN (Intra-amniotic injection of DIGOXIN) — Meir Medical Center. Intra-amniotic digoxin administration aims to treat fetal cardiac arrhythmias by crossing fetal membranes and exerting direct cardiac glycoside effects on fetal myocardium.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intra-amniotic injection of DIGOXIN TARGET	Intra-amniotic injection of DIGOXIN	Meir Medical Center	phase 3	Cardiac glycoside	Na+/K+-ATPase
DIGOXIN	DIGOXIN		marketed	Cardiac Glycoside [EPC]		1975-01-01
Lanoxin	digoxin	Generic (originally Burroughs Wellcome/GSK)	marketed	Cardiac Glycoside [EPC]	Nuclear receptor ROR-gamma, Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2	1954-01-01
Rate-control therapy	Rate-control therapy	Our Lady of the Lake Hospital	marketed	AV nodal blocking agents (beta-blockers, non-dihydropyridine calcium channel blockers, or cardiac glycosides)	AV nodal conduction (multiple targets depending on agent: beta-1 adrenergic receptors, L-type calcium channels, or adenosine receptors)
Cinobufacini Injection	Cinobufacini Injection	Dongfang Hospital Beijing University of Chinese Medicine	marketed	Natural product bufadienolide; cardiac glycoside analog	Na+/K+-ATPase; multiple apoptotic pathways
Digoxin (0.25mg)	Digoxin (0.25mg)	Advenchen Laboratories, LLC	phase 3	Cardiac glycoside	Na+/K+-ATPase
Magnesium sulfate and then Digoxin	Magnesium sulfate and then Digoxin	Sunnybrook Health Sciences Centre	phase 3	Electrolyte supplement and cardiac glycoside combination	Na+/K+-ATPase (digoxin); magnesium-dependent ion channels and enzymes (magnesium sulfate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cardiac glycoside class)

1. Advenchen Laboratories, LLC · 1 drug in this class
2. Meir Medical Center · 1 drug in this class
3. Nuvation Bio Inc. · 1 drug in this class